Osimertinib (AZD9291) is a third generation irreversible Tyrosine Kinase Inhibitor (TKI).

Irmukin (Osimertinib) is Indicated for the first-line treatment of patients with metastatic non-small cell lung cancer or NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations.

Irmukin (Osimertinib) is also indicated for metastatic EGFR T790M mutation positive NSCLC in patients who have progressed on or after EGFR TKI therapy